Cipla launches Niveoli HFA inhaler for adults

12 Apr 2019 Evaluate

Cipla has launched Niveoli, India’s first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways. Niveoli is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1427.50 70.55 (5.20%)
15-May-2024 10:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.25
Dr. Reddys Lab 5943.85
Cipla 1427.50
Zydus Lifesciences 1000.00
Lupin 1644.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.